Center for Dermatology Research, Department of Dermatology, Winston-Salem, NC, USA.
Department of Dermatology, Wake Forest Baptist Health, Winston-Salem, NC, USA.
Expert Rev Clin Immunol. 2024 Jul;20(7):695-702. doi: 10.1080/1744666X.2024.2326858. Epub 2024 Mar 14.
Vitiligo is a chronic, autoimmune condition characterized by skin depigmentation caused by inflammatory-mediated melanocyte degradation. Treatment of vitiligo is challenging due to the chronic nature of the condition. Ruxolitinib cream 1.5% was recently approved by the Food and Drug Administration (FDA) as a Janus kinase 1 and 2 inhibitor for use in nonsegmental vitiligo for those 12 years and older.
The purpose of this review is to describe the role of ruxolitinib in treating nonsegmental vitiligo.We searched PubMed using search terms nonsegmental vitiligo, jak inhibitor, and ruxolitinib. Clinicaltrials.gov was used to identify clinical trial data including efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability.
In both phase II and phase III (TRuE-V1 and TRuE-V2) trials, ruxolitinib cream 1.5% improved repigmentation with minimal adverse effects. Topical ruxolitinib is a much needed new vitiligo treatment option. Real life efficacy may not match that seen in clinical trials if the hurdle of poor adherence to topical treatment is not surmounted.
白癜风是一种慢性自身免疫性疾病，其特征是炎症介导的黑素细胞降解导致皮肤脱色。由于该疾病的慢性性质，白癜风的治疗具有挑战性。鲁索利替尼乳膏 1.5% 最近被美国食品和药物管理局 (FDA) 批准为 Janus 激酶 1 和 2 抑制剂，用于治疗 12 岁及以上的非节段性白癜风。
本综述旨在描述鲁索利替尼在治疗非节段性白癜风中的作用。我们使用非节段性白癜风、jak 抑制剂和鲁索利替尼等搜索词在 PubMed 上进行了搜索。Clinicaltrials.gov 用于确定临床研究数据，包括疗效、药效学、药代动力学、安全性和耐受性。
在两项 II 期和 III 期（TRuE-V1 和 TRuE-V2）试验中，鲁索利替尼乳膏 1.5% 改善了复色，不良反应最小。局部鲁索利替尼是一种急需的新的白癜风治疗选择。如果不能克服局部治疗依从性差的障碍，实际疗效可能与临床试验中观察到的疗效不一致。
